Citation

Gaston TE, Mendrick DL, Paine MF, Roe AL, Yeung CK. Regul. Toxicol. Pharmacol. 2020; 113: 104642.

Affiliation

Department of Pharmacy, University of Washington, United States. Electronic address: cathyy@uw.edu.

Copyright

(Copyright © 2020, Elsevier Publishing)

DOI

10.1016/j.yrtph.2020.104642

PMID

32197968

Abstract

During the 25 years since the US Congress passed the Dietary Supplement Health and Education Act (DSHEA), the law that transformed the US Food and Drug Administration's (FDA's) authority to regulate dietary supplements, the dietary supplement market has grown exponentially. Retail sales of herbal products, a subcategory of dietary supplements, have increased 83% from 2008 to 2018 ($4.8 to $8.8 billion USD). Although consumers often equate "natural" with "safe", it is well recognized by scientists that constituents in these natural products (NPs) can result in toxicity. Additionally, when NPs are co-consumed with pharmaceutical agents, the precipitant NP can alter drug disposition and drug delivery, thereby enhancing or reducing the therapeutic effect of the object drug(s). With the widespread use of NPs, these effects can be underappreciated. We present a summary of a symposium presented at the Annual Meeting of the Society of Toxicology 2019 (12 March 2019) that discussed potential toxicities of NPs alone and in combination with drugs.

Copyright © 2020 Elsevier Inc. All rights reserved.

Language: en

Keywords

Cannabis; Drug interactions; Medication safety; Natural products; Regulatory guidance